Home・Akciju saraksts・Alkermes PLC

Alkermes PLC

Atvērts

SektorsVeselības aprūpe

49.33 -1.54

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

49.05

Max

50.66

Galvenie mērījumi
By Trading Economics
Ienākumi	-116M -66M
Pārdošana	8.4M 393M
P/E Sektora vidējais	58.589 64.641
EPS	0.38
Peļņas marža	-16.92
Darbinieki	2,050
EBITDA	-98M -22M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+16.01% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 27. okt.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	3.1B 8.8B
Iepriekšējā atvēršanas cena	50.87
Iepriekšējā slēgšanas cena	49.33

Ziņu noskaņojums

By Acuity

10%

90%

5 / 340 Rangs Healthcare

Alkermes PLC Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. aug. 20:02 UTC

Alkermes shares are higher today, driven by significant gains in the overall market and major technology stocks, despite earlier session pullbacks.

2026. g. 31. jūl. 19:36 UTC

Alkermes Plc shares are lower today, impacted by declines in the Biotechnology sub-sector. The stock remains below its 20-day moving average.

2026. g. 30. jūl. 19:58 UTC

Alkermes Plc shares are higher during Thursday's session, reflecting a broader recovery in tech shares despite remaining below the 20-day moving average.

2026. g. 29. jūl. 20:03 UTC

News

Macro Event

Shares declining despite price target increases from JP Morgan, Baird.

2026. g. 28. jūl. 20:02 UTC

News

Event

Alkermes Plc shares are lower after reporting second-quarter earnings of 0 cents per share, below the consensus estimate of 29 cents.

2026. g. 24. jūl. 19:46 UTC

Alkermes Plc shares are lower today, pulling back after an early high. No specific news has been identified to explain the decline.

2026. g. 22. jūl. 19:36 UTC

Alkermes Plc shares are lower today, despite an earlier session high, amid rising crude oil prices and concerns over potential supply disruptions.

2026. g. 21. jūl. 18:46 UTC

Alkermes shares are higher today, supported by improved market sentiment and renewed interest in AI stocks. The asset is trading near its one-month range high.

2026. g. 20. jūl. 22:01 UTC

Alkermes Plc shares declined after-market, retracing from earlier peaks. The asset is currently below its 20-day moving average.

Salīdzinājums

Cenas izmaiņa

Alkermes PLC Prognoze

Cenas mērķis

By TipRanks

16.01% augšup

Prognoze 12 mēnešiem

Vidējais 57.46 USD 16.01%

Augstākais 65 USD

Zemākais 38 USD

Pamatojoties uz 13 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Alkermes PLC — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

13 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 13 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Alkermes PLC — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

5 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.